Anti-CD70 Immunocytokines for Exploitation of Interferon-γ-Induced RIP1-Dependent Necrosis in Renal Cell Carcinoma

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Chen, Peirong ^a   Nogusa, Shoko ^a   Thapa, Roshan J ^a   Shaller, Calvin ^a   Simmons, Heidi ^a   Peri, Suraj ^a   Adams, Gregory P ^a   Balachandran, Siddharth ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD70 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; STAT1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; KIDNEY CARCINOMA; NECROSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD70; ANTIVIRAL AGENTS; BORONIC ACIDS; CARCINOMA, RENAL CELL; CELL DEATH; CELL LINE, TUMOR; HUMANS; INTERFERON-GAMMA; KIDNEY NEOPLASMS; MICE; NECROSIS; PHOSPHORYLATION; PROTEIN BINDING; PYRAZINES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; STAT1 TRANSCRIPTION FACTOR;

MURINAE;

EID: 84876255774     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061446     Document Type: Article

References (54)

1. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, et al. (2011) The epidemiology of renal cell carcinoma. Eur Urol 60: 615-621.
2. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, et al. (1997) The Heidelberg classification of renal cell tumours. J Pathol 183: 131-133.
3. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, et al. (1997) Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 987-989.
4. Chen DY, Uzzo RG, (2011) Evaluation and management of the renal mass. Med Clin North Am 95: 179-189.
5. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
6. Hudes GR, (2009) Targeting mTOR in renal cell carcinoma. Cancer 115: 2313-2320.
7. Pal SK, Figlin RA, (2010) Targeted therapies for renal cell carcinoma: understanding their impact on survival. Target Oncol 5: 131-138.
8. Pirrotta MT, Bernardeschi P, Fiorentini G, (2011) Targeted-therapy in advanced renal cell carcinoma. Curr Med Chem 18: 1651-1657.
9. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, et al. (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev: CD001425.
10. Rosenblatt J, McDermott DF, (2011) Immunotherapy for renal cell carcinoma. Hematol Oncol Clin North Am 25: 793-812.
11. Wirth MP, (1993) Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283-295.
12. Machida T, Koiso K, Takaku F, Ogawa M, (1987) [Phase II study of recombinant human interferon gamma (S-6810) in renal cell carcinoma. Urological Cooperative Study Group of Recombinant Human Interferon Gamma (S-6810)]. Gan To Kagaku Ryoho 14: 440-445.
13. Miller CH, Maher SG, Young HA, (2009) Clinical Use of Interferon-gamma. Ann N Y Acad Sci 1182: 69-79.
14. Thapa RJ, Basagoudanavar SH, Nogusa S, Irrinki K, Mallilankaraman K, et al. (2011) NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis. Mol Cell Biol 31: 2934-2946.
15. Morais C, Gobe G, Johnson DW, Healy H, (2011) The emerging role of nuclear factor kappa B in renal cell carcinoma. Int J Biochem Cell Biol 43: 1537-1549.
16. Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N, et al. (2001) Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 20: 3888-3896.
17. An J, Rettig MB, (2007) Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 6: 61-69.
18. An J, Sun Y, Fisher M, Rettig MB, (2004) Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. Mol Cancer Ther 3: 727-736.
19. Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, et al. (2008) Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst 100: 649-662.
20. Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ, (2010) Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res 8: 729-738.
21. Roos FC, Roberts AM, Hwang, II, Moriyama EH, Evans AJ, et al. (2010) Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. EMBO Mol Med 2: 275-288.
22. Cvek B, Dvorak Z, (2011) The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. Curr Pharm Des 17: 1483-1499.
23. Chen D, Frezza M, Schmitt S, Kanwar J, Q PD, (2011) Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 11: 239-253.
24. Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, et al. (1985) Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res 45: 2866-2872.
25. Younes HM, Amsden BG, (2002) Interferon-gamma therapy: evaluation of routes of administration and delivery systems. J Pharm Sci 91: 2-17.
26. Pasche N, Neri D, (2012) Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 17: 583-590.
27. Ghetie V, Ward ES, (2002) Transcytosis and catabolism of antibody. Immunol Res 25: 97-113.
28. Mizokami MM, Hu P, Khawli LA, Li J, Epstein AL, (2003) Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid Hybridomics 22: 197-207.
29. Sharifi J, Khawli LA, Hu P, Li J, Epstein AL, (2002) Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid Hybridomics 21: 421-432.
30. Hornick JL, Sharifi J, Khawli LA, Hu P, Biela BH, et al. (1998) A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother Radiopharm 13: 255-268.
31. Boursalian TE, McEarchern JA, Law CL, Grewal IS, (2009) Targeting CD70 for human therapeutic use. Adv Exp Med Biol 647: 108-119.
32. Borst J, Hendriks J, Xiao Y, (2005) CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 17: 275-281.
33. Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, et al. (2006) Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 66: 2328-2337.
34. Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, et al. (2005) CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol 173: 2150-2153.
35. Diegmann J, Junker K, Gerstmayer B, Bosio A, Hindermann W, et al. (2005) Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. Eur J Cancer 41: 1794-1801.
36. Thrash-Bingham CA, Greenberg RE, Howard S, Bruzel A, Bremer M, et al. (1995) Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes. Proc Natl Acad Sci U S A 92: 2854-2858.
37. Mazor Y, Barnea I, Keydar I, Benhar I, (2007) Antibody internalization studied using a novel IgG binding toxin fusion. J Immunol Methods 321: 41-59.
38. McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, et al. (2007) Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 109: 1185-1192.
39. Fernandez M, Porosnicu M, Markovic D, Barber GN, (2002) Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 76: 895-904.
40. Balachandran S, Barber GN, (2007) PKR in innate immunity, cancer, and viral oncolysis. Methods Mol Biol 383: 277-301.
41. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
42. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD, (1998) How cells respond to interferons. Annu Rev Biochem 67: 227-264.
43. Platanias LC, (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5: 375-386.
44. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, et al. (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
45. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
46. Balachandran S, Barber GN, (2004) Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5: 51-65.
47. Balachandran S, Thomas E, Barber GN, (2004) A FADD-dependent innate immune mechanism in mammalian cells. Nature 432: 401-405.
48. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, et al. (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 4: 313-321.
49. Degterev A, Maki JL, Yuan J, (2013) Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ 20: 366.
50. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, et al. (2007) Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13: 4740-4749.
51. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, et al. (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338: 1265-1271.
52. Yang CH, Murti A, Pfeffer SR, Basu L, Kim JG, et al. (2000) IFNalpha/beta promotes cell survival by activating NF-kappa B. Proc Natl Acad Sci U S A. 97: 13631-13636.
53. Xuan C, Steward KK, Timmerman JM, Morrison SL, (2010) Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 115: 2864-2871.
54. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.